Drug delivery to macrophages: A review of targeting drugs and drug carriers to macrophages for inflammatory diseases

Schultze, 2018, Systems medicine in chronic inflammatory diseases, Immunity, 48, 608, 10.1016/j.immuni.2018.03.022 Murray, 2014, Macrophage activation and polarization: nomenclature and experimental guidelines, Immunity, 41, 14, 10.1016/j.immuni.2014.06.008 Martinez, 2014, 6 Piccolo, 2017, Opposing macrophage polarization programs show extensive epigenomic and transcriptional cross-talk, Nat. Immunol., 18, 530, 10.1038/ni.3710 Godsell, 2016, Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus, Sci. Rep., 6, 34601, 10.1038/srep34604 Jin, 2005, Lymphocyte apoptosis and macrophage function: correlation with disease activity in systemic lupus erythematosus, Clin. Rheumatol., 24, 107, 10.1007/s10067-004-0972-x Mellor-Pita, 2009, Monocytes and T lymphocytes contribute to a predominance of interleukin 6 and interleukin 10 in systemic lupus erythematosus, Cytometry B Clin. Cytom., 76b, 261, 10.1002/cyto.b.20468 Vogel, 2013, Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status, J. Neuroinflammation, 10, 10.1186/1742-2094-10-35 Soldano, 2018, Increase in circulating cells coexpressing M1 and M2 macrophage surface markers in patients with systemic sclerosis, Ann. Rheum. Dis., 77, 1842, 10.1136/annrheumdis-2018-213648 Arora, 2018, Macrophages: their role, activation and polarization in pulmonary diseases, Immunobiology, 223, 383, 10.1016/j.imbio.2017.11.001 Lee, 2019, Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide, J. Immunother. Cancer, 7, 147, 10.1186/s40425-019-0610-4 Abid, 2019, CCR2/CCR5-mediated macrophage-smooth muscle cell crosstalk in pulmonary hypertension, Eur. Respir. J., 54, 10.1183/13993003.02308-2018 Sica, 2012, Macrophage plasticity and polarization: in vivo veritas, J. Clin. Invest., 122, 787, 10.1172/JCI59643 Shields, 2019, Mater. Immunother., 1901633 Wei, 2017, Nanoparticle functionalization with platelet membrane enables multifactored biological targeting and detection of atherosclerosis, ACS Nano, 12, 109, 10.1021/acsnano.7b07720 Zhao, 2018, Fine tuning of core–shell structure of hyaluronic acid/cell-penetrating peptides/siRNA nanoparticles for enhanced gene delivery to macrophages in antiatherosclerotic therapy, Biomacromolecules, 19, 2944, 10.1021/acs.biomac.8b00501 Lee, 2015, Hyaluronic acid nanoparticles for active targeting atherosclerosis, Biomaterials, 53, 341, 10.1016/j.biomaterials.2015.02.089 Poh, 2017, Folate-targeted dendrimers selectively accumulate at sites of inflammation in mouse models of ulcerative colitis and atherosclerosis, Biomacromolecules, 18, 3082, 10.1021/acs.biomac.7b00728 He, 2018, Development of mannose functionalized dendrimeric nanoparticles for targeted delivery to macrophages: use of this platform to modulate atherosclerosis, Transl. Res., 193, 13, 10.1016/j.trsl.2017.10.008 Kim, 2018, Comparison of in vivo targeting ability between cRGD and collagen-targeting peptide conjugated nano-carriers for atherosclerosis, J. Control. Release, 269, 337, 10.1016/j.jconrel.2017.11.033 Qiao, 2017, Molecular imaging of vulnerable atherosclerotic plaques in vivo with osteopontin-specific upconversion nanoprobes, ACS Nano, 11, 1816, 10.1021/acsnano.6b07842 Nie, 2015, Detection of atherosclerotic lesions and intimal macrophages using CD36-targeted nanovesicles, J. Control. Release, 220, 61, 10.1016/j.jconrel.2015.10.004 Ye, 2019, SR-A-targeted phase-transition nanoparticles for the detection and treatment of atherosclerotic vulnerable plaques, ACS Appl. Mater. Interfaces, 11, 9702, 10.1021/acsami.8b18190 Coussens, 2002, Inflammation and cancer, Nature, 420, 860, 10.1038/nature01322 Cassetta, 2018, Targeting macrophages: therapeutic approaches in cancer, Nat. Rev. Drug Discov., 1 Qian, 2010, Macrophage diversity enhances tumor progression and metastasis, Cell, 141, 39, 10.1016/j.cell.2010.03.014 Edin, 2013, Macrophages: good guys in colorectal cancer, Oncoimmunology, 2, 10.4161/onci.23038 Welsh, 2005, Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer, J. Clin. Oncol., 23, 8959, 10.1200/JCO.2005.01.4910 Edin, 2012, The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer, PLoS One, 7, 10.1371/journal.pone.0047045 Pascual-Garcia, 2019, LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8(+) T cell tumor-infiltration impairing anti-PD1 therapy, Nat. Commun., 10, 2416, 10.1038/s41467-019-10369-9 Balkwill, 2012, Cancer-related inflammation: common themes and therapeutic opportunities, Semin. Cancer Biol., 22, 33, 10.1016/j.semcancer.2011.12.005 Ponzoni, 2018, Targeting macrophages as a potential therapeutic intervention: impact on inflammatory diseases and cancer, Int. J. Mol. Sci., 19, 1, 10.3390/ijms19071953 de Visser, 2006, Paradoxical roles of the immune system during cancer development, Nat. Rev. Cancer, 6, 24, 10.1038/nrc1782 Joyce, 2009, Microenvironmental regulation of metastasis, Nat. Rev. Cancer, 9, 239, 10.1038/nrc2618 Ruffell, 2015, Coussens, macrophages and therapeutic resistance in cancer, Cancer Cell, 27, 462, 10.1016/j.ccell.2015.02.015 Arlauckas, 2017, In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy, Sci. Transl. Med., 9, 10.1126/scitranslmed.aal3604 Muraoka, 2019, Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance, J. Clin. Invest., 129, 1278, 10.1172/JCI97642 Zhang, 2018, Current status and future directions of cancer immunotherapy, J. Cancer, 9, 1773, 10.7150/jca.24577 Schulz, 2012, A lineage of myeloid cells independent of Myb and hematopoietic stem cells, Science, 336, 86, 10.1126/science.1219179 Hoeffel, 2015, C-Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages, Immunity, 42, 665, 10.1016/j.immuni.2015.03.011 Guerriero, 2018, Macrophages: the road less traveled, changing anticancer therapy, Trends Mol. Med., 24, 472, 10.1016/j.molmed.2018.03.006 Lewis, 2006, Distinct role of macrophages in different tumor microenvironments, Cancer Res., 66, 605, 10.1158/0008-5472.CAN-05-4005 Murdoch, 2004, Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues, Blood, 104, 2224, 10.1182/blood-2004-03-1109 Madsen, 2017, Tumor-associated macrophages derived from circulating inflammatory monocytes degrade collagen through cellular uptake, Cell Rep., 21, 3662, 10.1016/j.celrep.2017.12.011 Sanford, 2013, Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis, Clin. Cancer Res., 19, 3404, 10.1158/1078-0432.CCR-13-0525 Pena, 2015, LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment, J. Clin. Invest., 125, 4063, 10.1172/JCI82152 Nywening, 2016, Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial, Lancet Oncol., 17, 651, 10.1016/S1470-2045(16)00078-4 Loberg, 2007, CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration, Neoplasia, 9, 556, 10.1593/neo.07307 Loberg, 2007, Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo, Cancer Res., 67, 9417, 10.1158/0008-5472.CAN-07-1286 Pienta, 2012, Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer, Investig. New Drugs, 31, 760, 10.1007/s10637-012-9869-8 Bonapace, 2014, Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis, Nature, 515, 130, 10.1038/nature13862 Moisan, 2014, Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers, Mol. Oncol., 8, 1231, 10.1016/j.molonc.2014.03.016 Cannarile, 2017, Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy, J. Immunother. Cancer, 5, 53, 10.1186/s40425-017-0257-y Cannarile, 2017, Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy, J. Immunother. Cancer, 5, 53, 10.1186/s40425-017-0257-y De Palma, 2005, Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors, Cancer Cell, 8, 211, 10.1016/j.ccr.2005.08.002 Wynn, 2013, Macrophage biology in development, homeostasis and disease, Nature, 496, 445, 10.1038/nature12034 Kowal, 2019, Re-education of macrophages as a therapeutic strategy in cancer, Immunotherapy, 11, 677, 10.2217/imt-2018-0156 Barclay, 2014, The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target, Annu. Rev. Immunol., 32, 25, 10.1146/annurev-immunol-032713-120142 Willingham, 2012, The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors, Proc. Natl. Acad. Sci. U. S. A., 109, 6662, 10.1073/pnas.1121623109 Badreddin Edris, 2012, Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma, Proc. Natl. Acad. Sci. U. S. A., 109, 6656, 10.1073/pnas.1121629109 Kulkarni, 2018, A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer, Nat. Biomed. Eng., 2, 589, 10.1038/s41551-018-0254-6 Chen, 2019, In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment, Nat. Nanotechnol., 14, 89, 10.1038/s41565-018-0319-4 Gholamin, 2017, Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors, Sci. Transl. Med., 9, 10.1126/scitranslmed.aaf2968 Huang, 2017, Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy, J. Thorac. Dis., 9, E168, 10.21037/jtd.2017.02.30 Petrova, 2017, TTI-621 (SIRPalphaFc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding, Clin. Cancer Res., 23, 1068, 10.1158/1078-0432.CCR-16-1700 Georgoudaki, 2016, Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis, Cell Rep., 15, 2000, 10.1016/j.celrep.2016.04.084 Khalil, 2007, Anti-CD40 agonist antibodies: preclinical and clinical experience, Update Cancer Ther., 2, 61, 10.1016/j.uct.2007.06.001 Ma, 2019, A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell-mediated anticancer activity, Cancer Immunol. Res., 7, 428, 10.1158/2326-6066.CIR-18-0061 Vonderheide, 2007, Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody, J. Clin. Oncol., 25, 876, 10.1200/JCO.2006.08.3311 Vonderheide, 2013, Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors, Oncoimmunology, 2, 10.4161/onci.23033 Nowak, 2015, A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma, Ann. Oncol., 26, 2483, 10.1093/annonc/mdv387 Beatty, 2013, A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma, Clin. Cancer Res., 19, 6286, 10.1158/1078-0432.CCR-13-1320 Ellmark, 2015, Kick-starting the cancer-immunity cycle by targeting CD40, Oncoimmunology, 4, 10.1080/2162402X.2015.1011484 Kaczanowska, 2013, TLR agonists: our best frenemy in cancer immunotherapy, J. Leukoc. Biol., 93, 847, 10.1189/jlb.1012501 Rodell, 2018, TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy, Nat. Biomed. Eng., 2, 578, 10.1038/s41551-018-0236-8 Chi, 2017, Anti-tumor activity of toll-like receptor 7 agonists, Front. Pharmacol., 8, 304, 10.3389/fphar.2017.00304 Weigel, 2012, Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies, Am. J. Hematol., 87, 953, 10.1002/ajh.23280 Smith, 2014, Antitumor activity and safety of combination therapy with the toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy, Cancer Immunol. Immunother., 63, 787, 10.1007/s00262-014-1547-6 Li, 2016, HDACs and HDAC inhibitors in cancer development and therapy, Cold Spring Harb. Perspect. Med., 6, 10.1101/cshperspect.a026831 Guerriero, 2017, Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages, Nature, 543, 428, 10.1038/nature21409 Kaneda, 2016, PI3Kgamma is a molecular switch that controls immune suppression, Nature, 539, 437, 10.1038/nature19834 Ha, 2014, Regulation of microRNA biogenesis, Nat. Rev. Mol. Cell Biol., 15, 509, 10.1038/nrm3838 Zhang, 2019, Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers, Nat. Commun., 10 Ortega, 2016, Manipulating the NF-κB pathway in macrophages using mannosylated, siRNA-delivering nanoparticles can induce immunostimulatory and tumor cytotoxic functions, Int. J. Nanomedicine, 11, 2163, 10.2147/IJN.S93483 Qian, 2017, Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages, ACS Nano, 11, 9536, 10.1021/acsnano.7b05465 Ortega, 2015, Biocompatible mannosylated endosomal-escape nanoparticles enhance selective delivery of short nucleotide sequences to tumor associated macrophages, Nanoscale, 7, 500, 10.1039/C4NR03962A Parayath, 2018, Repolarization of tumor-associated macrophages in a genetically engineered nonsmall cell lung cancer model by intraperitoneal administration of hyaluronic acid-based nanoparticles encapsulating microRNA-125b, Nano Lett., 18, 3571, 10.1021/acs.nanolett.8b00689 Baer, 2016, Suppression of microRNA activity amplifies IFN-gamma-induced macrophage activation and promotes anti-tumour immunity, Nat. Cell Biol., 18, 790, 10.1038/ncb3371 Ovais, 2019, Tailoring nanomaterials for targeting tumor-associated macrophages, Adv. Mater., 31, 1808303, 10.1002/adma.201808303 Huang, 2012, Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy, J. Control. Release, 158, 286, 10.1016/j.jconrel.2011.11.013 Song, 2016, Bioconjugated manganese dioxide nanoparticles enhance chemotherapy response by priming tumor-associated macrophages toward M1-like phenotype and attenuating tumor hypoxia, ACS Nano, 10, 633, 10.1021/acsnano.5b06779 Zanganeh, 2016, Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues, Nat. Nanotechnol., 11, 986, 10.1038/nnano.2016.168 Wang, 2017, Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment, Biomaterials, 112, 153, 10.1016/j.biomaterials.2016.09.034 Shi, 2018, Reprogramming tumor-associated macrophages by nanoparticle-based reactive oxygen species photogeneration, Nano Lett., 18, 7330, 10.1021/acs.nanolett.8b03568 Choo, 2018, M1 macrophage-derived nanovesicles potentiate the anticancer efficacy of immune checkpoint inhibitors, ACS Nano, 12, 8977, 10.1021/acsnano.8b02446 Barker, 2015, The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence, Nat. Rev. Cancer, 15, 409, 10.1038/nrc3958 Teresa Pinto, 2016, Ionizing radiation modulates human macrophages towards a pro-inflammatory phenotype preserving their pro-invasive and pro-angiogenic capacities, Sci. Rep., 6, 18765, 10.1038/srep18765 Pusuluri, 2019, Immunological consequences of chemotherapy: single drugs, combination therapies and nanoparticle-based treatments, J. Control. Release, 305, 130, 10.1016/j.jconrel.2019.04.020 Yan, 2017, Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas, Oncogene, 36, 6049, 10.1038/onc.2017.261 Tap, 2015, Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor, N. Engl. J. Med., 373, 428, 10.1056/NEJMoa1411366 Strachan, 2013, CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T cells, Oncoimmunology, 2, 10.4161/onci.26968 Pyonteck, 2013, CSF-1R inhibition alters macrophage polarization and blocks glioma progression, Nat. Med., 19, 1264, 10.1038/nm.3337 von Tresckow, 2015, An open-label, multicenter, phase I/II study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory Hodgkin lymphoma, Clin. Cancer Res., 21, 1843, 10.1158/1078-0432.CCR-14-1845 Ries, 2014, Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy, Cancer Cell, 25, 846, 10.1016/j.ccr.2014.05.016 Cassier, 2015, CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study, Lancet Oncol., 16, 949, 10.1016/S1470-2045(15)00132-1 Qiu, 2018, Tumor-associated macrophages in breast cancer: innocent bystander or important player?, Cancer Treat. Rev., 70, 178, 10.1016/j.ctrv.2018.08.010 Papadopoulos, 2017, First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors, Clin. Cancer Res., 23, 5703, 10.1158/1078-0432.CCR-16-3261 Rooijen, 1994, Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications, J. Immunol. Methods, 174, 83, 10.1016/0022-1759(94)90012-4 Banciu, 2008, Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue, Neoplasia, 10, 108, 10.1593/neo.07913 Zeisberger, 2006, Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach, Br. J. Cancer, 95, 272, 10.1038/sj.bjc.6603240 Piaggio, 2016, A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: anti-angiogenic and anti-tumor effects, J. Control. Release, 223, 165, 10.1016/j.jconrel.2015.12.037 Zhan, 2014, Targeted depletion of tumour-associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy, Biomaterials, 35, 10046, 10.1016/j.biomaterials.2014.09.007 Fritz, 2014, Depletion of tumor-associated macrophages slows the growth of chemically induced mouse lung adenocarcinomas, Front. Immunol., 5, 587, 10.3389/fimmu.2014.00587 Bader, 2018, Macrophage depletion using clodronate liposomes decreases tumorigenesis and alters gut microbiota in the AOM/DSS mouse model of colon cancer, Am. J. Physiol. Gastrointest. Liver Physiol., 314, G22, 10.1152/ajpgi.00229.2017 Wu, 2014, Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo, J. Invest. Dermatol., 134, 2814, 10.1038/jid.2014.206 Griesmann, 2017, Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer, Gut, 66, 1278, 10.1136/gutjnl-2015-310049 Opperman, 2019, Clodronate-liposome mediated macrophage depletion abrogates multiple myeloma tumor establishment in vivo, Neoplasia, 21, 777, 10.1016/j.neo.2019.05.006 Van Acker, 2016, Bisphosphonates for cancer treatment: mechanisms of action and lessons from clinical trials, Pharmacol. Ther., 158, 24, 10.1016/j.pharmthera.2015.11.008 Germano, 2013, Role of macrophage targeting in the antitumor activity of trabectedin, Cancer Cell, 23, 249, 10.1016/j.ccr.2013.01.008 Liguori, 2016, Functional TRAIL receptors in monocytes and tumor-associated macrophages: a possible targeting pathway in the tumor microenvironment, Oncotarget, 7, 41662, 10.18632/oncotarget.9340 Germano, 2010, Antitumor and anti-inflammatory effects of trabectedin on human Myxoid Liposarcoma cells, Cancer Res., 70, 2235, 10.1158/0008-5472.CAN-09-2335 Allavena, 2005, Anti-inflammatory properties of the novel antitumor agent yondelis (Trabectedin): inhibition of macrophage differentiation and cytokine production, Cancer Res., 65, 2964, 10.1158/0008-5472.CAN-04-4037 Purnama, 2014, Transient ablation of alveolar macrophages leads to massive pathology of influenza infection without affecting cellular adaptive immunity, Eur. J. Immunol., 44, 2003, 10.1002/eji.201344359 Ma, 2019, The role of monocytes and macrophages in autoimmune diseases: a comprehensive review, Front. Immunol., 10, 1140, 10.3389/fimmu.2019.01140 Navegantes, 2017, Immune modulation of some autoimmune diseases: the critical role of macrophages and neutrophils in the innate and adaptive immunity, J. Transl. Med., 15, 36, 10.1186/s12967-017-1141-8 Lee, 2016, Macrophage-based cell therapies: the long and winding road, J. Control. Release, 240, 527, 10.1016/j.jconrel.2016.07.018 Udalova, 2016, Macrophage heterogeneity in the context of rheumatoid arthritis, Nat. Rev. Rheumatol., 12, 472, 10.1038/nrrheum.2016.91 Sack, 1994, Distribution of macrophages in rheumatoid synovial membrane and its association with basic activity, Rheumatol. Int., 13, 181, 10.1007/BF00390265 Mulherin, 1996, Synovial tissue macrophage populations and articular damage in rheumatoid arthritis, Arthritis Rheum., 39, 115, 10.1002/art.1780390116 Fukui, 2017, M1 and M2 monocytes in rheumatoid arthritis: a contribution of imbalance of M1/M2 monocytes to osteoclastogenesis, Front. Immunol., 8, 1958, 10.3389/fimmu.2017.01958 Soler Palacios, 2015, Macrophages from the synovium of active rheumatoid arthritis exhibit an activin A-dependent pro-inflammatory profile, J. Pathol., 235, 515, 10.1002/path.4466 Yamanaka, 2015, TNF as a target of inflammation in rheumatoid arthritis, Endocr Metab Immune Disord Drug Targets, 15, 129, 10.2174/1871530315666150316121808 Semerano, 2014, Targeting IL-6 for the treatment of rheumatoid arthritis: phase II investigational drugs, Expert Opin. Investig. Drugs, 23, 979, 10.1517/13543784.2014.912276 Pope, 2013, Possible roles of IL-12-family cytokines in rheumatoid arthritis, Nat. Rev. Rheumatol., 9, 252, 10.1038/nrrheum.2012.170 Scott, 1997, Rheumatoid arthritis synovial fibroblast and U937 macrophage/monocyte cell line interaction in cartilage degradation, Arthritis Rheum., 40, 490, 10.1002/art.1780400315 Misharin, 2014, Nonclassical Ly6C(−) monocytes drive the development of inflammatory arthritis in mice, Cell Rep., 9, 591, 10.1016/j.celrep.2014.09.032 Scott, 2010, Rheumatoid arthritis, Lancet, 376, 1094, 10.1016/S0140-6736(10)60826-4 Van Lent, 1998, Local removal of phagocytic synovial lining cells by clodronate-liposomes decreases cartilage destruction during collagen type II arthritis, Ann. Rheum. Dis., 57, 408, 10.1136/ard.57.7.408 Park, 2016, SIRT1 inhibits differentiation of monocytes to macrophages: amelioration of synovial inflammation in rheumatoid arthritis, J. Mol. Med. (Berl.), 94, 921, 10.1007/s00109-016-1402-7 van Roon, 2003, Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin, Arthritis Rheum., 48, 1229, 10.1002/art.10940 van Vuuren, 2006, CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model, J. Immunol., 176, 5833, 10.4049/jimmunol.176.10.5833 Ye, 2014, Interleukin-10 attenuation of collagen-induced arthritis is associated with suppression of interleukin-17 and retinoid-related orphan receptor gammat production in macrophages and repression of classically activated macrophages, Arthritis Res. Ther., 16, R96, 10.1186/ar4544 Chen, 2017, IL-33/ST2-mediated inflammation in macrophages is directly abrogated by IL-10 during rheumatoid arthritis, Oncotarget, 8, 32407, 10.18632/oncotarget.16299 Park, 2017, SIRT1/adenosine monophosphate-activated protein kinase alpha signaling enhances macrophage polarization to an anti-inflammatory phenotype in rheumatoid arthritis, Front. Immunol., 8, 1135, 10.3389/fimmu.2017.01135 Sun, 2017, Targeting notch-activated M1 macrophages attenuates joint tissue damage in a mouse model of inflammatory arthritis, J. Bone Miner. Res., 32, 1469, 10.1002/jbmr.3117 Shin, 2016, Human umbilical cord blood-stem cells direct macrophage polarization and block inflammasome activation to alleviate rheumatoid arthritis, Cell Death Dis., 7, 10.1038/cddis.2016.442 Lee, 2019, Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis, Nat. Mater. Mosquera, 2019, Immunomodulatory nanogels overcome restricted immunity in a murine model of gut microbiome-mediated metabolic syndrome, Sci. Adv., 5, 10.1126/sciadv.aav9788 van Schouwenburg, 2013, Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis, Nat. Rev. Rheumatol., 9, 164, 10.1038/nrrheum.2013.4 Donlin, 2014, Modulation of TNF-induced macrophage polarization by synovial fibroblasts, J. Immunol., 193, 2373, 10.4049/jimmunol.1400486 Yarilina, 2012, Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors, Arthritis Rheum., 64, 3856, 10.1002/art.37691 Deshpande, 2013, IL-7- and IL-15-mediated TCR sensitization enables T cell responses to self-antigens, J. Immunol., 190, 1416, 10.4049/jimmunol.1201620 Baslund, 2005, Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study, Arthritis Rheum., 52, 2686, 10.1002/art.21249 Jain, 2015, Macrophage repolarization with targeted alginate nanoparticles containing IL-10 plasmid DNA for the treatment of experimental arthritis, Biomaterials, 61, 162, 10.1016/j.biomaterials.2015.05.028 van Nieuwenhuijze, 2013, GM-CSF as a therapeutic target in inflammatory diseases, Mol. Immunol., 56, 675, 10.1016/j.molimm.2013.05.002 Burmester, 2014, Emerging cell and cytokine targets in rheumatoid arthritis, Nat. Rev. Rheumatol., 10, 77, 10.1038/nrrheum.2013.168 Burmester, 2013, Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis, Ann. Rheum. Dis., 72, 1445, 10.1136/annrheumdis-2012-202450 Weiss, 2015, IRF5 controls both acute and chronic inflammation, Proc. Natl. Acad. Sci. U. S. A., 112, 11001, 10.1073/pnas.1506254112 Machado, 2018, Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study, Arthritis Res. Ther., 20, 60, 10.1186/s13075-018-1539-6 Magnusson, 2016, Macrophage and dendritic cell subsets in IBD: ALDH+ cells are reduced in colon tissue of patients with ulcerative colitis regardless of inflammation, Mucosal Immunol., 9, 171, 10.1038/mi.2015.48 Demetter, 2005, Colon mucosa of patients both with spondyloarthritis and Crohn’s disease is enriched with macrophages expressing the scavenger receptor CD163, Ann. Rheum. Dis., 64, 321, 10.1136/ard.2003.018382 Kuhl, 2015, Diversity of intestinal macrophages in inflammatory bowel diseases, Front. Immunol., 6, 613, 10.3389/fimmu.2015.00613 Smith, 2009, Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn’s disease, J. Exp. Med., 206, 1883, 10.1084/jem.20091233 Goldstein, 2011, Defective leukocyte GM-CSF receptor (CD116) expression and function in inflammatory bowel disease, Gastroenterology, 141, 208, 10.1053/j.gastro.2011.03.060 Na, 2019, Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD, Nat. Rev. Gastroenterol. Hepatol., 16, 531, 10.1038/s41575-019-0172-4 Bailey, 2012, IL-13 promotes collagen accumulation in Crohn's disease fibrosis by down-regulation of fibroblast MMP synthesis: a role for innate lymphoid cells?, PLoS One, 7, 10.1371/journal.pone.0052332 Bouma, 2003, The immunological and genetic basis of inflammatory bowel disease, Nat. Rev. Immunol., 3, 521, 10.1038/nri1132 Zhou, 2015, 18beta-glycyrrhetinic acid suppresses experimental autoimmune encephalomyelitis through inhibition of microglia activation and promotion of remyelination, Sci. Rep., 5, 13713, 10.1038/srep13713 Cosin-Roger, 2013, M2 macrophages activate WNT signaling pathway in epithelial cells: relevance in ulcerative colitis, PLoS One, 8, 10.1371/journal.pone.0078128 Kamada, 2009, Human CD14+ macrophages in intestinal lamina propria exhibit potent antigen-presenting ability, J. Immunol., 183, 1724, 10.4049/jimmunol.0804369 Kamada, 2010, TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn’s disease, Inflamm. Bowel Dis., 16, 568, 10.1002/ibd.21124 Kamada, 2008, Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis, J. Clin. Invest., 118, 2269 Ogino, 2013, Increased Th17-inducing activity of CD14+ CD163 low myeloid cells in intestinal lamina propria of patients with Crohn’s disease, Gastroenterology, 145, 1380, 10.1053/j.gastro.2013.08.049 Liu, 2011, The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity, J. Leukoc. Biol., 89, 597, 10.1189/jlb.0810456 Kobayashi, 2008, IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease, Gut, 57, 1682, 10.1136/gut.2007.135053 Globig, 2014, Comprehensive intestinal T helper cell profiling reveals specific accumulation of IFN-gamma+IL-17+coproducing CD4+ T cells in active inflammatory bowel disease, Inflamm. Bowel Dis., 20, 2321, 10.1097/MIB.0000000000000210 Lissner, 2015, Monocyte and M1 macrophage-induced barrier defect contributes to chronic intestinal inflammation in IBD, Inflamm. Bowel Dis., 21, 1297 Haribhai, 2016, Alternatively activated macrophages boost induced regulatory T and Th17 cell responses during immunotherapy for colitis, J. Immunol., 196, 3305, 10.4049/jimmunol.1501956 Zhu, 2016, The pentacyclic triterpene Lupeol switches M1 macrophages to M2 and ameliorates experimental inflammatory bowel disease, Int. Immunopharmacol., 30, 74, 10.1016/j.intimp.2015.11.031 Song, 2017, TSG-6 secreted by human adipose tissue-derived mesenchymal stem cells ameliorates DSS-induced colitis by inducing M2 macrophage polarization in mice, Sci. Rep., 7, 5187, 10.1038/s41598-017-04766-7 Seo, 2017, Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease, Sci. Rep., 7, 851, 10.1038/s41598-017-00840-2 Kanai, 2015, A breakthrough in probiotics: Clostridium butyricum regulates gut homeostasis and anti-inflammatory response in inflammatory bowel disease, J. Gastroenterol., 50, 928, 10.1007/s00535-015-1084-x Liu, 2015, Treatment of dextran sodium sulfate-induced experimental colitis by adoptive transfer of peritoneal cells, Sci. Rep., 5, 16760, 10.1038/srep16760 Vos, 2012, Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro, Inflamm. Bowel Dis., 18, 401, 10.1002/ibd.21818 Vos, 2011, Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner, Gastroenterology, 140, 221, 10.1053/j.gastro.2010.10.008 Lucas, 2005, ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus, J. Immunol., 175, 469, 10.4049/jimmunol.175.1.469 Pander, 2011, Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab, Clin. Cancer Res., 17, 5668, 10.1158/1078-0432.CCR-11-0239 Colombel, 2010, Infliximab, azathioprine, or combination therapy for Crohn’s disease, N. Engl. J. Med., 362, 1383, 10.1056/NEJMoa0904492 Marshall, 2015, Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer, PLoS One, 10, 10.1371/journal.pone.0127063 Ito, 2004, A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease, Gastroenterology, 126, 989, 10.1053/j.gastro.2004.01.012 Mannon, 2004, Anti-interleukin-12 antibody for active Crohn’s disease, N. Engl. J. Med., 351, 2069, 10.1056/NEJMoa033402 Liu, 2017, The pathogenic role of NLRP3 inflammasome activation in inflammatory bowel diseases of both mice and humans, J. Crohn’s Colitis, 11, 737 Sandborn, 2017, Tofacitinib as induction and maintenance therapy for ulcerative colitis, N. Engl. J. Med., 376, 1723, 10.1056/NEJMoa1606910 Panes, 2017, Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials, Gut, 66, 1049, 10.1136/gutjnl-2016-312735 Spadaccini, 2017, PDE4 inhibition and inflammatory bowel disease: a novel therapeutic avenue, Int. J. Mol. Sci., 18, 10.3390/ijms18061276 Mazur, 2015, Inhibitors of phosphodiesterase 4 (PDE 4): a new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis, J. Dermatolog. Treat., 26, 326, 10.3109/09546634.2014.991267 Sabino, 2019, New biologics and small molecules in inflammatory bowel disease: an update, Ther. Adv. Gastroenterol., 12, 10.1177/1756284819853208 Nylander, 2012, Multiple sclerosis, J. Clin. Invest., 122, 1180, 10.1172/JCI58649 Thompson, 2018, Multiple sclerosis, Lancet, 391, 1622, 10.1016/S0140-6736(18)30481-1 Bramow, 2010, Demyelination versus remyelination in progressive multiple sclerosis, Brain, 133, 2983, 10.1093/brain/awq250 Mallucci, 2015, The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis, Prog. Neurobiol., 127–128, 1, 10.1016/j.pneurobio.2015.02.003 van der Valk, 2000, Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS, Neuropathol. Appl. Neurobiol., 26, 2, 10.1046/j.1365-2990.2000.00217.x Moll, 2011, Multiple sclerosis normal-appearing white matter: pathology-imaging correlations, Ann. Neurol., 70, 764, 10.1002/ana.22521 Tambalo, 2015, Functional magnetic resonance imaging of rats with experimental autoimmune encephalomyelitis reveals brain cortex remodeling, J. Neurosci., 35, 10088, 10.1523/JNEUROSCI.0540-15.2015 Planche, 2017, Selective dentate gyrus disruption causes memory impairment at the early stage of experimental multiple sclerosis, Brain Behav. Immun., 60, 240, 10.1016/j.bbi.2016.11.010 Zrzavy, 2017, Loss of 'homeostatic' microglia and patterns of their activation in active multiple sclerosis, Brain, 140, 1900, 10.1093/brain/awx113 Tannahill, 2013, Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha, Nature, 496, 238, 10.1038/nature11986 Kigerl, 2009, Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord, J. Neurosci., 29, 13435, 10.1523/JNEUROSCI.3257-09.2009 Peferoen, 2015, Activation status of human microglia is dependent on lesion formation stage and remyelination in multiple sclerosis, J. Neuropathol. Exp. Neurol., 74, 48, 10.1097/NEN.0000000000000149 Inoue, 2012, NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis, Proc. Natl. Acad. Sci. U. S. A., 109, 10480, 10.1073/pnas.1201836109 Zhang, 2017, Silencing c-Rel in macrophages dampens Th1 and Th17 immune responses and alleviates experimental autoimmune encephalomyelitis in mice, Immunol. Cell Biol., 95, 593, 10.1038/icb.2017.11 Holz, 2018, Differing outcome of experimental autoimmune encephalitis in macrophage/neutrophil- and T cell-specific gp130-deficient mice, Front. Immunol., 9, 836, 10.3389/fimmu.2018.00836 Wang, 2018, Nr4a1 plays a crucial modulatory role in Th1/Th17 cell responses and CNS autoimmunity, Brain Behav. Immun., 68, 44, 10.1016/j.bbi.2017.09.015 Bsibsi, 2014, Demyelination during multiple sclerosis is associated with combined activation of microglia/macrophages by IFN-gamma and alpha B-crystallin, Acta Neuropathol., 128, 215, 10.1007/s00401-014-1317-8 Hill, 2004, Inducible nitric oxide synthase in chronic active multiple sclerosis plaques: distribution, cellular expression and association with myelin damage, J. Neuroimmunol., 151, 171, 10.1016/j.jneuroim.2004.02.005 Giacomini, 2013, IFN-beta therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients, Eur. J. Immunol., 43, 1963, 10.1002/eji.201243212 Huitinga, 1990, Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages, J. Exp. Med., 172, 1025, 10.1084/jem.172.4.1025 Heppner, 2005, Experimental autoimmune encephalomyelitis repressed by microglial paralysis, Nat. Med., 11, 146, 10.1038/nm1177 Moreno, 2016, Therapeutic depletion of monocyte-derived cells protects from long-term axonal loss in experimental autoimmune encephalomyelitis, J. Neuroimmunol., 290, 36, 10.1016/j.jneuroim.2015.11.004 Tran, 1998, Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice, J. Immunol., 161, 3767, 10.4049/jimmunol.161.7.3767 Miron, 2013, M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination, Nat. Neurosci., 16, 1211, 10.1038/nn.3469 Liu, 2013, Targeting the shift from M1 to M2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil, PLoS One, 8 Peruzzotti-Jametti, 2018, Macrophage-derived extracellular succinate licenses neural stem cells to suppress chronic neuroinflammation, Cell Stem Cell, 22, 355, 10.1016/j.stem.2018.01.020 Jiang, 2012, IL-33 attenuates EAE by suppressing IL-17 and IFN-gamma production and inducing alternatively activated macrophages, Eur. J. Immunol., 42, 1804, 10.1002/eji.201141947 Weber, 2007, Type II monocytes modulate T cell-mediated central nervous system autoimmune disease, Nat. Med., 13, 935, 10.1038/nm1620 Burger, 2009, Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis, Proc. Natl. Acad. Sci. U. S. A., 106, 4355, 10.1073/pnas.0812183106 Nally, 2019, Nanomodulation of macrophages in multiple sclerosis, Cells, 8, 10.3390/cells8060543 Bao, 2016, CXCR7 suppression modulates microglial chemotaxis to ameliorate experimentally-induced autoimmune encephalomyelitis, Biochem. Biophys. Res. Commun., 469, 1, 10.1016/j.bbrc.2015.11.059 Koch, 2015, Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis, J. Neurol. Sci., 358, 131, 10.1016/j.jns.2015.08.1525 Wang, 2019, Targeting microglia and macrophages: a potential treatment strategy for multiple sclerosis, Front. Pharmacol., 10, 286, 10.3389/fphar.2019.00286 Djedovic, 2017, Anti-encephalitogenic effects of ethyl pyruvate are reflected in the central nervous system and the gut, Biomed. Pharmacother., 96, 78, 10.1016/j.biopha.2017.09.110 Veremeyko, 2018, Cyclic AMP pathway suppress autoimmune neuroinflammation by inhibiting functions of encephalitogenic CD4 T cells and enhancing M2 macrophage polarization at the site of inflammation, Front. Immunol., 9, 50, 10.3389/fimmu.2018.00050 Kornberg, 2018, Bryostatin-1 alleviates experimental multiple sclerosis, Proc. Natl. Acad. Sci. U. S. A., 115, 2186, 10.1073/pnas.1719902115 Fan, 2018, A novel PADRE-Kv1.3 vaccine effectively induces therapeutic antibodies and ameliorates experimental autoimmune encephalomyelitis in rats, Clin. Immunol., 193, 98, 10.1016/j.clim.2018.02.012 Montes-Cobos, 2017, Deletion of the mineralocorticoid receptor in myeloid cells attenuates central nervous system autoimmunity, Front. Immunol., 8, 1319, 10.3389/fimmu.2017.01319 Montes-Cobos, 2017, Targeted delivery of glucocorticoids to macrophages in a mouse model of multiple sclerosis using inorganic-organic hybrid nanoparticles, J. Control. Release, 245, 157, 10.1016/j.jconrel.2016.12.003 Lloyd, 2019, The pro-remyelination properties of microglia in the central nervous system, Nat. Rev. Neurol., 15, 447, 10.1038/s41582-019-0184-2 Wang, 2015, Quetiapine inhibits microglial activation by neutralizing abnormal STIM1-mediated intercellular calcium homeostasis and promotes myelin repair in a cuprizone-induced mouse model of demyelination, Front. Cell. Neurosci., 9, 492, 10.3389/fncel.2015.00492 Laflamme, 2018, mCSF-induced microglial activation prevents myelin loss and promotes its repair in a mouse model of multiple sclerosis, Front. Cell. Neurosci., 12, 178, 10.3389/fncel.2018.00178 Natrajan, 2015, Retinoid X receptor activation reverses age-related deficiencies in myelin debris phagocytosis and remyelination, Brain, 138, 3581, 10.1093/brain/awv289 Mori, 2015, Effects of 3,3′,5-triiodothyronine on microglial functions, Glia, 63, 906, 10.1002/glia.22792 Zhang, 2015, Thyroid hormone alleviates demyelination induced by cuprizone through its role in remyelination during the remission period, Exp. Biol. Med. (Maywood), 240, 1183, 10.1177/1535370214565975 Lima, 2001, Regulation of microglial development: a novel role for thyroid hormone, J. Neurosci., 21, 2028, 10.1523/JNEUROSCI.21-06-02028.2001 Mullin, 2017, rHIgM22 enhances remyelination in the brain of the cuprizone mouse model of demyelination, Neurobiol. Dis., 105, 142, 10.1016/j.nbd.2017.05.015 Zorina, 2018, Human IgM antibody rHIgM22 promotes phagocytic clearance of myelin debris by microglia, Sci. Rep., 8, 9392, 10.1038/s41598-018-27559-y Serada, 2008, IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis, Proc. Natl. Acad. Sci. U. S. A., 105, 9041, 10.1073/pnas.0802218105 Van Weyenbergh, 2001, Treatment of multiple sclerosis patients with interferon-beta primes monocyte-derived macrophages for apoptotic cell death, J. Leukoc. Biol., 70, 745, 10.1189/jlb.70.5.745 Inui, 2016, Case report: GcMAF treatment in a patient with multiple sclerosis, Anticancer Res., 36, 3771 Xue, 2017, Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence, Nat. Nanotechnol., 12, 692, 10.1038/nnano.2017.54 Hou, 2019, Accessing neuroinflammation sites: Monocyte/neutrophil-mediated drug delivery for cerebral ischemia, Sci. Adv., 5, eaau8301, 10.1126/sciadv.aau8301 Brynskikh, 2010, Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson’s disease, Nanomedicine, 5, 379, 10.2217/nnm.10.7 Klyachko, 2017, Macrophages with cellular backpacks for targeted drug delivery to the brain, Biomaterials, 140, 79, 10.1016/j.biomaterials.2017.06.017 Gatto, 2019, New therapeutic strategies in systemic lupus erythematosus management, Nat. Rev. Rheumatol., 15, 30, 10.1038/s41584-018-0133-2 Baumann, 2002, Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus, Arthritis Rheum., 46, 191, 10.1002/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO;2-K Kavai, 2007, Immune complex clearance by monocytes and macrophages in systemic lupus erythematosus, Autoimmun. Rev., 6, 497, 10.1016/j.autrev.2007.01.017 Herrmann, 1998, Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus, Arthritis Rheum., 41, 1241, 10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H Blanco, 2001, Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus, Science, 294, 1540, 10.1126/science.1064890 Decker, 2006, Monocyte-derived dendritic cells over-express CD86 in patients with systemic lupus erythematosus, Rheumatology (Oxford), 45, 1087, 10.1093/rheumatology/kel061 Katsiari, 2002, Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus, Clin. Immunol., 103, 54, 10.1006/clim.2001.5172 Desai-Mehta, 1996, Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production, J. Clin. Invest., 97, 2063, 10.1172/JCI118643 Koshy, 1996, Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes, J. Clin. Invest., 98, 826, 10.1172/JCI118855 Orme, 2012, Macrophages and neutrophils in SLE-An online molecular catalog, Autoimmun. Rev., 11, 365, 10.1016/j.autrev.2011.10.010 Biesen, 2008, Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus, Arthritis Rheum., 58, 1136, 10.1002/art.23404 Umare, 2014, Effect of proinflammatory cytokines (IL-6, TNF-alpha, and IL-1beta) on clinical manifestations in Indian SLE patients, Mediat. Inflamm., 2014, 385297, 10.1155/2014/385297 Harigai, 2008, Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B, J. Immunol., 181, 2211, 10.4049/jimmunol.181.3.2211 Santer, 2009, Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus, J. Immunol., 182, 1192, 10.4049/jimmunol.182.2.1192 Wagrowska-Danilewicz, 2005, Correlative insights into immunoexpression of monocyte chemoattractant protein-1, transforming growth factor beta-1 and CD68+ cells in lupus nephritis, Pol. J. Pathol., 56, 115 Bennett, 2003, Interferon and granulopoiesis signatures in systemic lupus erythematosus blood, J. Exp. Med., 197, 711, 10.1084/jem.20021553 Uchida, 2019, Anti-IL-10 antibody in systemic lupus erythematosus, Open Access Rheumatol., 11, 61, 10.2147/OARRR.S191953 Hedrich, 2014, Stat3 promotes IL-10 expression in lupus T cells through trans-activation and chromatin remodeling, Proc. Natl. Acad. Sci. U. S. A., 111, 13457, 10.1073/pnas.1408023111 Sharif, 2004, IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis, J. Immunol., 172, 6476, 10.4049/jimmunol.172.10.6476 Aringer, 2002, Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death, Lupus, 11, 102, 10.1191/0961203302lu160oa Grondal, 2000, Cytokine production, serum levels and disease activity in systemic lupus erythematosus, Clin. Exp. Rheumatol., 18, 565 Yang, 2015, Sex-dependent differential activation of NLRP3 and AIM2 inflammasomes in SLE macrophages, Rheumatology (Oxford), 54, 324, 10.1093/rheumatology/keu318 Sahu, 2014, Structure and function of renal macrophages and dendritic cells from lupus-prone mice, Arthritis Rheum., 66, 1596, 10.1002/art.38410 Li, 2015, Macrophage polarization modulates development of systemic lupus erythematosus, Cell. Physiol. Biochem., 37, 1279, 10.1159/000430251 Mohammadi, 2017, Immunomodulation in systemic lupus erythematosus: induction of M2 population in monocyte-derived macrophages by pioglitazone, Lupus, 26, 1318, 10.1177/0961203317701842 Mohammadi, 2018, Sodium valproate modulates immune response by alternative activation of monocyte-derived macrophages in systemic lupus erythematosus, Clin. Rheumatol., 37, 719, 10.1007/s10067-017-3922-0 Mohammadi, 2018, Immunoregulatory effects of indole-3-carbinol on monocyte-derived macrophages in systemic lupus erythematosus: a crucial role for aryl hydrocarbon receptor, Autoimmunity, 51, 199, 10.1080/08916934.2018.1494161 Llorente, 2000, Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus, Arthritis Rheum., 43, 1790, 10.1002/1529-0131(200008)43:8<1790::AID-ANR15>3.0.CO;2-2 Tackey, 2004, Rationale for interleukin-6 blockade in systemic lupus erythematosus, Lupus, 13, 339, 10.1191/0961203304lu1023oa Illei, 2010, Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study, Arthritis Rheum., 62, 542, 10.1002/art.27221 Aringer, 2004, Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study, Arthritis Rheum., 50, 3161, 10.1002/art.20576 Aringer, 2009, Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients, Rheumatology (Oxford), 48, 1451, 10.1093/rheumatology/kep270 Liu, 2017, Enhanced Inflammasome activity in systemic lupus erythematosus is mediated via type I interferon-induced up-regulation of interferon regulatory factor 1, Arthritis Rheum., 69, 1840, 10.1002/art.40166 Chalmers, 2015, Therapeutic targeting of macrophages in lupus nephritis, Discov. Med., 20, 43 Calderon, 2006, In CD4+ T-cell-induced diabetes, macrophages are the final effector cells that mediate islet beta-cell killing: studies from an acute model, Am. J. Pathol., 169, 2137, 10.2353/ajpath.2006.060539 O’Brien, 2006, A deficiency in the in vivo clearance of apoptotic cells is a feature of the NOD mouse, J. Autoimmun., 26, 104, 10.1016/j.jaut.2005.11.006 Maree, 2005, Quantifying macrophage defects in type 1 diabetes, J. Theor. Biol., 233, 533, 10.1016/j.jtbi.2004.10.030 Thayer, 2011, Superoxide production by macrophages and T cells is critical for the induction of autoreactivity and type 1 diabetes, Diabetes, 60, 2144, 10.2337/db10-1222 Vomund, 2015, Beta cells transfer vesicles containing insulin to phagocytes for presentation to T cells, Proc. Natl. Acad. Sci. U. S. A., 112, E5496, 10.1073/pnas.1515954112 Marro, 2019, Macrophage IFN-I signaling promotes autoreactive T cell infiltration into islets in type 1 diabetes model, JCI Insight, 4, 10.1172/jci.insight.125067 Devaraj, 2006, Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes, Diabetes, 55, 774, 10.2337/diabetes.55.03.06.db05-1417 Arif, 2004, Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health, J. Clin. Invest., 113, 451, 10.1172/JCI19585 Antonelli, 2008, Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed type 1 diabetes: a longitudinal study, Diabet. Med., 25, 1349 Bradshaw, 2009, Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells, J. Immunol., 183, 4432, 10.4049/jimmunol.0900576 Uno, 2007, Macrophages and dendritic cells infiltrating islets with or without beta cells produce tumour necrosis factor-alpha in patients with recent-onset type 1 diabetes, Diabetologia, 50, 596, 10.1007/s00125-006-0569-9 Lechleitner, 2000, Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors, J. Intern. Med., 248, 67, 10.1046/j.1365-2796.2000.00705.x Albiero, 2015, Bone marrow macrophages contribute to diabetic stem cell mobilopathy by producing oncostatin M, Diabetes, 64, 2957, 10.2337/db14-1473 Ferris, 2017, The islet-resident macrophage is in an inflammatory state and senses microbial products in blood, J. Exp. Med., 214, 2369, 10.1084/jem.20170074 Carrero, 2016, Macrophages and dendritic cells in islets of Langerhans in diabetic autoimmunity: a lesson on cell interactions in a mini-organ, Curr. Opin. Immunol., 43, 54, 10.1016/j.coi.2016.09.004 Mastrandrea, 2009, Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study, Diabetes Care, 32, 1244, 10.2337/dc09-0054 Tack, 2009, Development of type 1 diabetes in a patient treated with anti-TNF-alpha therapy for active rheumatoid arthritis, Diabetologia, 52, 1442, 10.1007/s00125-009-1381-0 Parsa, 2012, Adoptive transfer of immunomodulatory M2 macrophages prevents type 1 diabetes in NOD mice, Diabetes, 61, 2881, 10.2337/db11-1635 Zheng, 2011, Transfused macrophages ameliorate pancreatic and renal injury in murine diabetes mellitus, Nephron Exp. Nephrol., 118, e87, 10.1159/000321034 Daneshmandi, 2017, TGF-beta engineered mesenchymal stem cells (TGF-beta/MSCs) for treatment of type 1 diabetes (T1D) mice model, Int. Immunopharmacol., 44, 191, 10.1016/j.intimp.2017.01.019 Carrero, 2017, Resident macrophages of pancreatic islets have a seminal role in the initiation of autoimmune diabetes of NOD mice, Proc. Natl. Acad. Sci. U. S. A., 114, E10418, 10.1073/pnas.1713543114 Jiang, 2017, Local release of dexamethasone from macroporous scaffolds accelerates islet transplant engraftment by promotion of anti-inflammatory M2 macrophages, Biomaterials, 114, 71, 10.1016/j.biomaterials.2016.11.004 Al-Salama, 2018, Baricitinib: a review in rheumatoid arthritis, Drugs, 78, 761, 10.1007/s40265-018-0908-4 Degboe, 2019, Polarization of rheumatoid macrophages by TNF targeting through an IL-10/STAT3 mechanism, Front. Immunol., 10, 3, 10.3389/fimmu.2019.00003 Weber, 2011, Atherosclerosis: current pathogenesis and therapeutic options, Nat. Med., 17, 1410, 10.1038/nm.2538 Basatemur, 2019, Vascular smooth muscle cells in atherosclerosis, Nat. Rev. Cardiol., 16, 727, 10.1038/s41569-019-0227-9 Moore, 2011, Tabas, macrophages in the pathogenesis of atherosclerosis, Cell, 145, 341, 10.1016/j.cell.2011.04.005 Bäck, 2019, Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities, Nat. Rev. Cardiol., 16, 389 Kamaly, 2016, Targeted interleukin-10 nanotherapeutics developed with a microfluidic chip enhance resolution of inflammation in advanced atherosclerosis, ACS Nano, 10, 5280, 10.1021/acsnano.6b01114 Alaarg, 2017, A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis, J. Control. Release, 262, 47, 10.1016/j.jconrel.2017.07.013 Tsigkas, 2016, Drug-loaded particles: "Trojan horses" in the therapy of atherosclerosis, Atherosclerosis, 251, 528, 10.1016/j.atherosclerosis.2016.06.050 Tang, 2015, Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation, Sci. Adv., 1, 10.1126/sciadv.1400223 Nguyen, 2019, Delivery of MicroRNAs by chitosan nanoparticles to functionally alter macrophage cholesterol efflux in vitro and in vivo, ACS Nano, 13, 6491, 10.1021/acsnano.8b09679 Sun, 2014, Systemic delivery of microRNA-181b inhibits nuclear factor-kappaB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice, Circ. Res., 114, 32, 10.1161/CIRCRESAHA.113.302089 Zhao, 2018, Co-delivery of LOX-1 siRNA and statin to endothelial cells and macrophages in the atherosclerotic lesions by a dual-targeting core-shell nanoplatform: a dual cell therapy to regress plaques, J. Control. Release, 283, 241, 10.1016/j.jconrel.2018.05.041 Chen, 2019, miR-378a modulates macrophage phagocytosis and differentiation through targeting CD47-SIRPα axis in atherosclerosis, Scand. J. Immunol., 90, 10.1111/sji.12766 Henrich, 2019, Supramolecular assembly of high-density lipoprotein mimetic nanoparticles using lipid-conjugated core scaffolds, J. Am. Chem. Soc., 141, 9753, 10.1021/jacs.9b00651 Zimmer, 2016, Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming, Sci. Transl. Med., 8, 10.1126/scitranslmed.aad6100 Leavy, 2016, Macrophages: dissolving cholesterol to unclog arteries, Nat. Rev. Immunol., 16, 274, 10.1038/nri.2016.50 Wang, 2018, Targeted therapy of atherosclerosis by a broad-spectrum reactive oxygen species scavenging nanoparticle with intrinsic anti-inflammatory activity, ACS Nano, 12, 8943, 10.1021/acsnano.8b02037 Jiang, 2019, Rational design of lovastatin-loaded spherical reconstituted high density lipoprotein for efficient and safe anti-atherosclerotic therapy, Mol. Pharm., 16, 3284, 10.1021/acs.molpharmaceut.9b00445 Lu, 2017, Biofunctional polymer–lipid hybrid high-density lipoprotein-mimicking nanoparticles loading anti-miR155 for combined antiatherogenic effects on macrophages, Biomacromolecules, 18, 2286, 10.1021/acs.biomac.7b00436 Beldman, 2017, Hyaluronan nanoparticles selectively target plaque-associated macrophages and improve plaque stability in atherosclerosis, ACS Nano, 11, 5785, 10.1021/acsnano.7b01385 Fredman, 2015, Targeted nanoparticles containing the proresolving peptide Ac2–26 protect against advanced atherosclerosis in hypercholesterolemic mice, Sci. Transl. Med., 7, 10.1126/scitranslmed.aaa1065 Ridker, 2017, Antiinflammatory therapy with canakinumab for atherosclerotic disease, N. Engl. J. Med., 377, 1119, 10.1056/NEJMoa1707914 Nakashiro, 2016, Pioglitazone-incorporated nanoparticles prevent plaque destabilization and rupture by regulating monocyte/macrophage differentiation in ApoE−/− mice, Arterioscler. Thromb. Vasc. Biol., 36, 491, 10.1161/ATVBAHA.115.307057 Katsuki, 2014, Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes, Circulation, 129, 896, 10.1161/CIRCULATIONAHA.113.002870 Spiller, 2015, Sequential delivery of immunomodulatory cytokines to facilitate the M1-to-M2 transition of macrophages and enhance vascularization of bone scaffolds, Biomaterials, 37, 194, 10.1016/j.biomaterials.2014.10.017 Alvarez, 2016, Delivery strategies to control inflammatory response: modulating M1–M2 polarization in tissue engineering applications, J. Control. Release, 240, 349, 10.1016/j.jconrel.2016.01.026 Kamaly, 2013, Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles, Proc. Natl. Acad. Sci. U. S. A., 110, 6506, 10.1073/pnas.1303377110 Li, 2019, A Proresolving peptide nanotherapy for site-specific treatment of inflammatory bowel disease by regulating proinflammatory microenvironment and gut microbiota, Adv. Sci., 1900610 Leoni, 2015, Annexin A1–containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair, J. Clin. Invest., 125, 1215, 10.1172/JCI76693 She, 2016, Plaque-penetrating peptide inhibits development of hypoxic atherosclerotic plaque, J. Control. Release, 238, 212, 10.1016/j.jconrel.2016.07.020 Wang, 2019, Biomimetic nanotherapies: red blood cell based core–shell structured nanocomplexes for atherosclerosis management, Adv. Sci., 6, 1900172, 10.1002/advs.201900172 Lameijer, 2018, Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates, Nat. Biomed. Eng., 2, 279, 10.1038/s41551-018-0221-2 Kojima, 2017, The role of efferocytosis in atherosclerosis, Circulation, 135, 476, 10.1161/CIRCULATIONAHA.116.025684 Kojima, 2016, CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis, Nature, 536, 86, 10.1038/nature18935 Yang, 2011, Efficient cytosolic delivery of siRNA using HDL-mimicking nanoparticles, Small, 7, 568, 10.1002/smll.201001589 Zhang, 2009, Biomimetic nanocarrier for direct cytosolic drug delivery, Angew. Chem. Int. Ed. Eng., 48, 9171, 10.1002/anie.200903112 Rabinovitch, 2012, Molecular pathogenesis of pulmonary arterial hypertension, J. Clin. Invest., 122, 4306, 10.1172/JCI60658 Rabinovitch, 2014, Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension, Circ. Res., 115, 165, 10.1161/CIRCRESAHA.113.301141 Lai, 2014, Pulmonary arterial hypertension: the clinical syndrome, Circ. Res., 115, 115, 10.1161/CIRCRESAHA.115.301146 McLaughlin, 2009, J. Am. Coll. Cardiol., 53, 1573, 10.1016/j.jacc.2009.01.004 Price, 2012, Inflammation in pulmonary arterial hypertension, Chest, 141, 210, 10.1378/chest.11-0793 Tian, 2013, Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension, Sci. Transl. Med., 5, 10.1126/scitranslmed.3006674 Thenappan, 2011, A central role for CD68 (+) macrophages in hepatopulmonary syndrome: reversal by macrophage depletion, Am. Respir. Crit. Care Med., 183, 1080, 10.1164/rccm.201008-1303OC Park, 2019, Assessment of inflammation in pulmonary artery hypertension by 68Ga-mannosylated human serum albumin, Am. Respir. Crit. Care Med. Vergadi, 2011, Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension, Circulation, 123, 1986, 10.1161/CIRCULATIONAHA.110.978627 Žaloudíková, 2016, Depletion of alveolar macrophages attenuates hypoxic pulmonary hypertension but not hypoxia-induced increase in serum concentration of MCP-1, Physiol. Res., 65, 763, 10.33549/physiolres.933187 Crosswhite, 2014, AAV delivery of tumor necrosis factor-α short hairpin RNA attenuates cold-induced pulmonary hypertension and pulmonary arterial remodeling, Hypertension, 64, 1141, 10.1161/HYPERTENSIONAHA.114.03791 Chen, 2011, Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension, Hypertension, 57, 343, 10.1161/HYPERTENSIONAHA.110.157032 Lee, 2018, Cerivastatin nanoliposome as a potential disease modifying approach for the treatment of pulmonary arterial hypertension, J. Pharmacol. Exp.Ther., 366, 66, 10.1124/jpet.118.247643 Hartwig, 2014, Depletion of alveolar macrophages ameliorates virus-induced disease following a pulmonary coronavirus infection, PLoS One, 9, 10.1371/journal.pone.0090720 Mathie, 2015, Alveolar macrophages are sentinels of murine pulmonary homeostasis following inhaled antigen challenge, Allergy, 70, 80, 10.1111/all.12536 Abid, 2019, CCR2/CCR5-mediated macrophage-smooth muscle cell crosstalk in pulmonary hypertension, Eur. Respir. J., 54, 1802308, 10.1183/13993003.02308-2018 Hashimoto-Kataoka, 2015, Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension, Proc. Natl. Acad. Sci. U. S. A., 112, 10.1073/pnas.1424774112 Scott, 2019, Inflammasomes: a novel therapeutic target in pulmonary hypertension?, Br. J. Pharmacol., 176, 1880, 10.1111/bph.14375 Bai, 2019, Macrophage-derived legumain promotes pulmonary hypertension by activating the MMP (matrix metalloproteinase)-2/TGF (transforming growth factor)-β1 signaling, Arterioscler. Thromb. Vasc. Biol., 39, e130, 10.1161/ATVBAHA.118.312254 Sagar, 2012, Myocarditis, Lancet, 379, 738, 10.1016/S0140-6736(11)60648-X Li, 2009, Differential macrophage polarization in male and female BALB/c mice infected with Coxsackievirus B3 defines susceptibility to viral myocarditis, Circ. Res., 105, 353, 10.1161/CIRCRESAHA.109.195230 Jia, 2017, Gold nanoparticle-based miR155 antagonist macrophage delivery restores the cardiac function in ovariectomized diabetic mouse model, Int. J. Nanomedicine, 12, 4963, 10.2147/IJN.S138400 Farajzadeh, 2018, Macrophage repolarization using CD44-targeting hyaluronic acid–polylactide nanoparticles containing curcumin, Artif. Cells Nanomed. Biotechnol., 46, 2013 Shimizu, 2019, Anti-inflammatory action of curcumin and its use in the treatment of lifestyle-related diseases, Eur. Cardiol., 14, 117, 10.15420/ecr.2019.17.2 Zhang, 2018, Water-dispersible PEG-curcumin/amine-functionalized covalent organic framework nanocomposites as smart carriers for in vivo drug delivery, Nat. Commun., 9, 2785, 10.1038/s41467-018-04910-5 Cooper, 2014, Nano-scale treatment for a macro-scale disease: nanoparticle-delivered siRNA silences CCR2 and treats myocarditis, Eur. Heart J., 36, 1434, 10.1093/eurheartj/ehu302 Leuschner, 2014, Silencing of CCR2 in myocarditis, Eur. Heart J., 36, 1478, 10.1093/eurheartj/ehu225 Amoah, 2015, Immunopathogenesis of myocarditis: the interplay between cardiac fibroblast cells, dendritic cells, macrophages and CD 4+ T cells, Scand. J. Immunol., 82, 1, 10.1111/sji.12298 Takahama, 2009, Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats, J. Am. Coll. Cardiol., 53, 709, 10.1016/j.jacc.2008.11.014 Okuda, 2016, Targeted therapy for acute autoimmune myocarditis with nano-sized liposomal FK506 in rats, PLoS One, 11, 10.1371/journal.pone.0160944 Dick, 2019, Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction, Nat. Immunol., 20, 29, 10.1038/s41590-018-0272-2 Frangogiannis, 2017, The extracellular matrix in myocardial injury, repair, and remodeling, J. Clin. Invest., 127, 1600, 10.1172/JCI87491 Fujiwara, 2019, Nanoparticle incorporating toll-like receptor 4 inhibitor attenuates myocardial ischaemia–reperfusion injury by inhibiting monocyte-mediated inflammation in mice, Cardiovasc. Res., 115, 1244, 10.1093/cvr/cvz066 Guillen, 1995, Cytokine signaling during myocardial infarction: sequential appearance of IL-1 beta and IL-6, Am. J. Phys., 269, R229 Sager Hendrik, 2015, Targeting interleukin-1β reduces leukocyte production after acute myocardial infarction, Circulation, 132, 1880, 10.1161/CIRCULATIONAHA.115.016160 Crossman, 2017, The canakinumab antiinflammatory thrombosis outcome study trial—the starting gun has fired, J. Thorac. Dis., 9, 4922, 10.21037/jtd.2017.11.96 Díaz-Herráez, 2017, Transplantation of adipose-derived stem cells combined with neuregulin-microparticles promotes efficient cardiac repair in a rat myocardial infarction model, J. Control. Release, 249, 23, 10.1016/j.jconrel.2017.01.026 Bejerano, 2018, Nanoparticle delivery of miRNA-21 mimic to cardiac macrophages improves myocardial remodeling after myocardial infarction, Nano Lett., 18, 5885, 10.1021/acs.nanolett.8b02578 Han, 2018, Dual roles of graphene oxide to attenuate inflammation and elicit timely polarization of macrophage phenotypes for cardiac repair, ACS Nano, 12, 1959, 10.1021/acsnano.7b09107 Ben-Mordechai, 2017, Targeting and modulating infarct macrophages with hemin formulated in designed lipid-based particles improves cardiac remodeling and function, J. Control. Release, 257, 21, 10.1016/j.jconrel.2017.01.001 Heymans, 2013, Macrophage microRNA-155 promotes cardiac hypertrophy and failure, Circulation, 128, 1420, 10.1161/CIRCULATIONAHA.112.001357 Hu, 2019, Inhibition of microRNA-155 attenuates sympathetic neural remodeling following myocardial infarction via reducing M1 macrophage polarization and inflammatory responses in mice, Eur. J. Pharmacol., 851, 122, 10.1016/j.ejphar.2019.02.001 Pascual-Gil, 2019, NRG1 PLGA MP locally induce macrophage polarisation toward a regenerative phenotype in the heart after acute myocardial infarction, J. Drug Target., 27, 573, 10.1080/1061186X.2018.1531417 Garbayo, 2016, Catheter-based intramyocardial injection of FGF1 or NRG1-loaded MPs improves cardiac function in a preclinical model of ischemia-reperfusion, Sci. Rep., 6, 25932, 10.1038/srep25932 Feiner, 2018, Multifunctional degradable electronic scaffolds for cardiac tissue engineering, J. Control. Release, 281, 189, 10.1016/j.jconrel.2018.05.023 Allijn, 2017, Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction, J. Control. Release, 247, 127, 10.1016/j.jconrel.2016.12.042 Whyte, 2018, Sustained release of targeted cardiac therapy with a replenishable implanted epicardial reservoir, Nat. Biomed. Eng., 2, 416, 10.1038/s41551-018-0247-5 Matsumura, 2019, Intramyocardial injection of a fully synthetic hydrogel attenuates left ventricular remodeling post myocardial infarction, Biomaterials, 119289, 10.1016/j.biomaterials.2019.119289 Tang, 2018, Cardiac cell–integrated microneedle patch for treating myocardial infarction, Sci. Adv., 4, 10.1126/sciadv.aat9365 Purcell, 2018, Delivery of a matrix metalloproteinase-responsive hydrogel releasing TIMP-3 after myocardial infarction: effects on left ventricular remodeling, Am. J. Physiol. Heart Circ. Physiol., 315, H814, 10.1152/ajpheart.00076.2018 Montgomery, 2017, Flexible shape-memory scaffold for minimally invasive delivery of functional tissues, Nat. Mater., 16, 1038, 10.1038/nmat4956 Nguyen, 2015, Enzyme-responsive nanoparticles for targeted accumulation and prolonged retention in heart tissue after myocardial infarction, Adv. Mater., 27, 5547, 10.1002/adma.201502003 Carlini, 2019, Enzyme-responsive progelator cyclic peptides for minimally invasive delivery to the heart post-myocardial infarction, Nat. Commun., 10, 1735, 10.1038/s41467-019-09587-y Afratis, 2018, The apparent competitive action of ECM proteases and cross-linking enzymes during fibrosis: applications to drug discovery, Adv. Drug Deliv. Rev., 129, 4, 10.1016/j.addr.2018.03.004 Hinderer, 2019, Cardiac fibrosis – a short review of causes and therapeutic strategies, Adv. Drug Deliv. Rev., 146, 77, 10.1016/j.addr.2019.05.011 Purcell, 2014, Injectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibition, Nat. Mater., 13, 653, 10.1038/nmat3922 Falkenham, 2015, Nonclassical resident macrophages are important determinants in the development of myocardial fibrosis, Am. J. Pathol., 185, 927, 10.1016/j.ajpath.2014.11.027 McDonald, 2018, Increased macrophage-derived SPARC precedes collagen deposition in myocardial fibrosis, Am. J. Physiol. Heart Circ. Physiol., 315, H92, 10.1152/ajpheart.00719.2017 Heymann, 2009, Monocytes and macrophages as cellular targets in liver fibrosis, Inflamm. Allergy Drug Targets, 8, 307, 10.2174/187152809789352230 Harel-Adar, 2011, Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair, Proc. Natl. Acad. Sci. U. S. A., 108, 1827, 10.1073/pnas.1015623108 Zhao, 2018, Targeting chondroitin sulfate glycosaminoglycans to treat cardiac fibrosis in pathological remodeling, Circulations, 137, 2497, 10.1161/CIRCULATIONAHA.117.030353 Vong, 2018, Novel angiogenesis therapeutics by redox injectable hydrogel-regulation of local nitric oxide generation for effective cardiovascular therapy, Biomaterials, 167, 143, 10.1016/j.biomaterials.2018.03.023 Hasan, 2015, Injectable hydrogels for cardiac tissue repair after myocardial infarction, Adv. Sci., 2, 1500122, 10.1002/advs.201500122 Reyes-Martínez, 2019, Advanced hydrogels for treatment of diabetes, J. Tissue Eng. Regen. Med., 13, 1375, 10.1002/term.2880 Ashtari, 2019, Electrically conductive nanomaterials for cardiac tissue engineering, Adv. Drug Deliv. Rev., 144, 162, 10.1016/j.addr.2019.06.001 Hsu, 2019, Adaptable microporous hydrogels of propagating NGF-gradient by injectable building blocks for accelerated axonal outgrowth, Adv. Sci., 6, 1900520, 10.1002/advs.201900520 Le, 2018, Injectable hyaluronic acid based microrods provide local micromechanical and biochemical cues to attenuate cardiac fibrosis after myocardial infarction, Biomaterials, 169, 11, 10.1016/j.biomaterials.2018.03.042 Wang, 2019, Hyaluronic acid oligosaccharides improve myocardial function reconstruction and angiogenesis against myocardial infarction by regulation of macrophages, Theranostics, 9, 1980, 10.7150/thno.31073 Dou, 2016, Sustained delivery by a cyclodextrin material-based nanocarrier potentiates antiatherosclerotic activity of rapamycin via selectively inhibiting mTORC1 in mice, J. Control. Release, 235, 48, 10.1016/j.jconrel.2016.05.049 Mansukhani, 2019, Peptide amphiphile supramolecular nanostructures as a targeted therapy for atherosclerosis, Macromol. Biosci., 19, 1900066, 10.1002/mabi.201900066 Sharma, 2018, Macrophage-derived extracellular vesicles mediate smooth muscle hyperplasia: role of altered miRNA cargo in response to HIV infection and substance abuse, FASEB J., 32, 5174, 10.1096/fj.201701558R Liang, 2019, A dual fluorescent reverse targeting drug delivery system based on curcumin-loaded ovalbumin nanoparticles for allergy treatment, Nanomedicine, 16, 56, 10.1016/j.nano.2018.11.010 Davies, 2013, Tissue-resident macrophages, Nat. Immunol., 14, 986, 10.1038/ni.2705 Sommerfeld, 2019, Interleukin-36gamma-producing macrophages drive IL-17-mediated fibrosis, Sci. Immunol., 4, 10.1126/sciimmunol.aax4783 Heo, 2019, Molecular imaging visualizes recruitment of inflammatory monocytes and macrophages to the injured heart, Circ. Res., 124, 881, 10.1161/CIRCRESAHA.118.314030 Aghighi, 2018, Magnetic resonance imaging of tumor-associated macrophages: clinical translation, Clin. Cancer Res., 24, 4110, 10.1158/1078-0432.CCR-18-0673 Weissleder, 2014, Imaging macrophages with nanoparticles, Nat. Mater., 13, 125, 10.1038/nmat3780 Kim, 2018, Quantitative imaging of tumor-associated macrophages and their response to therapy using 64Cu-labeled macrin, ACS Nano, 12, 12015, 10.1021/acsnano.8b04338 Cooke, 2018, Inflammation-targeted vascular nanomedicine, Nat. Biomed. Eng., 2, 269, 10.1038/s41551-018-0241-y Everett, 2018, Anti-inflammatory therapy with canakinumab and reduction in total cardiovascular events, Circulation, 138 Zhao, 2019, Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers, Adv. Drug Deliv. Rev., 143, 3, 10.1016/j.addr.2019.01.002 He, 2019, Adapting liposomes for oral drug delivery, Acta Pharm. Sin. B, 1, 36, 10.1016/j.apsb.2018.06.005